171 related articles for article (PubMed ID: 38584282)
1. Machine learning pipeline to analyze clinical and proteomics data: experiences on a prostate cancer case.
Vizza P; Aracri F; Guzzi PH; Gaspari M; Veltri P; Tradigo G
BMC Med Inform Decis Mak; 2024 Apr; 24(1):93. PubMed ID: 38584282
[TBL] [Abstract][Full Text] [Related]
2. Benchmarking of Machine Learning classifiers on plasma proteomic for COVID-19 severity prediction through interpretable artificial intelligence.
Dimitsaki S; Gavriilidis GI; Dimitriadis VK; Natsiavas P
Artif Intell Med; 2023 Mar; 137():102490. PubMed ID: 36868685
[TBL] [Abstract][Full Text] [Related]
3. Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables.
Gabriele C; Aracri F; Prestagiacomo LE; Rota MA; Alba S; Tradigo G; Guzzi PH; Cuda G; Damiano R; Veltri P; Gaspari M
Clin Proteomics; 2023 Nov; 20(1):52. PubMed ID: 37990292
[TBL] [Abstract][Full Text] [Related]
4. Proteomics in diagnosis of prostate cancer.
Davalieva K; Polenakovic M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
[TBL] [Abstract][Full Text] [Related]
5. Machine-learning Algorithm-based Risk Prediction and Screening-detected Prostate Cancer in A Benign Prostate Hyperplasia Cohort.
Chang CC; Chiou JK; Lin CJ; Lu K; Li JR; Chang LW; Hung SC; Cheng CL
Anticancer Res; 2024 Apr; 44(4):1683-1693. PubMed ID: 38537959
[TBL] [Abstract][Full Text] [Related]
6. A peptide-centric approach to analyse quantitative proteomics data- an application to prostate cancer biomarker discovery.
Lima T; Rodrigues JE; Manadas B; Henrique R; Fardilha M; Vitorino R
J Proteomics; 2023 Feb; 272():104774. PubMed ID: 36427804
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry.
Adeola HA; Soares NC; Paccez JD; Kaestner L; Blackburn JM; Zerbini LF
Proteomics Clin Appl; 2015 Jun; 9(5-6):597-609. PubMed ID: 25708745
[TBL] [Abstract][Full Text] [Related]
8. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
9. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer.
He J; Han Z; Luo W; Shen J; Xie F; Liao L; Zou G; Luo X; Guo Z; Li Y; Li J; Chen H
Front Immunol; 2022; 13():998447. PubMed ID: 36685547
[TBL] [Abstract][Full Text] [Related]
10. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
Wang W; He Z; Kong Y; Liu Z; Gong L
Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
[TBL] [Abstract][Full Text] [Related]
11. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine.
Principe S; Kim Y; Fontana S; Ignatchenko V; Nyalwidhe JO; Lance RS; Troyer DA; Alessandro R; Semmes OJ; Kislinger T; Drake RR; Medin JA
J Proteome Res; 2012 Apr; 11(4):2386-96. PubMed ID: 22339264
[TBL] [Abstract][Full Text] [Related]
12. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
13. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
14. An improved machine learning pipeline for urinary volatiles disease detection: Diagnosing diabetes.
Martinez-Vernon AS; Covington JA; Arasaradnam RP; Esfahani S; O'Connell N; Kyrou I; Savage RS
PLoS One; 2018; 13(9):e0204425. PubMed ID: 30261000
[TBL] [Abstract][Full Text] [Related]
15. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
Zhao H; Zhao X; Lei T; Zhang M
Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
[TBL] [Abstract][Full Text] [Related]
16. Machine learning application for incident prostate adenocarcinomas automatic registration in a French regional cancer registry.
Fabacher T; Godet J; Klein D; Velten M; Jegu J
Int J Med Inform; 2020 Jul; 139():104139. PubMed ID: 32330852
[TBL] [Abstract][Full Text] [Related]
17. Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-Seq datasets and machine learning.
Gupta R; Kleinjans J; Caiment F
BMC Cancer; 2021 Aug; 21(1):962. PubMed ID: 34445986
[TBL] [Abstract][Full Text] [Related]
18. Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers.
Zhang M; Chen L; Yuan Z; Yang Z; Li Y; Shan L; Yin B; Fei X; Miao J; Song Y
Discov Med; 2016 Nov; 22(122):281-295. PubMed ID: 28009970
[TBL] [Abstract][Full Text] [Related]
19. Enhancing the prediction of IDC breast cancer staging from gene expression profiles using hybrid feature selection methods and deep learning architecture.
Kishore A; Venkataramana L; Prasad DVV; Mohan A; Jha B
Med Biol Eng Comput; 2023 Nov; 61(11):2895-2919. PubMed ID: 37530887
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
